Monograph Details
|
|
Gastrointestinal Tract
> Nausea
|
|
CESAMET |
| Manufacturer |
|
Valeant Pharmaceuticals, Inc |
| Legal Classification |
|
CII |
| Pharmacological Class |
|
Cannabinoid. |
| Generic Name |
|
Nabilone 1mg; caps. |
| Indications |
|
Treatment of nausea and vomiting associated with cancer chemotherapy in patients who have not responded adequately to other antiemetics. |
| Children |
<18yrs: not recommended.
|
| Adults |
|
1–2mg twice daily; max 6mg/day in 3 divided doses. Give 1st dose 1–3 hours before chemotherapy is administered; use lower starting dose and increase if necessary. May give 1–2mg the night before chemo. Continue 2–3 doses/day during chemotherapy course, if needed, may continue 48 hours after each chemo cycle. |
| Precautions |
|
Hypertension. Heart disease. History of psychiatric disorders (eg, bipolar disorder, depression, schizophrenia) or substance abuse. Write Rx for limited quantity (ie, enough for one chemotherapy course). Keep patient under responsible adult supervision (esp. when dose is adjusted). Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Potentiates CNS depression with benzodiazepines, barbiturates, alcohol, other CNS depressants and other psychoactive substances (avoid). May affect, or be affected by, other drugs that undergo first-pass hepatic metabolism or that are highly protein bound (eg, sympathomimetics, anticholinergics, tricyclic antidepressants). Cross-tolerance and mutual potentiation with opioids. Naltrexone: see literature. |
| Adverse Reactions |
|
Drowsiness, vertigo, dry mouth, euphoria/dysphoria, ataxia, headache, tachycardia, hypotension, concentration difficulties, sleep disturbance, other psychiatric reactions (may persist for several days after dosing), changes in appetite. |
| How Supplied |
|
Caps—20 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
